Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2011-08-31 Capital/Financing Update
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 172.4KB
Capital/Financing Update Classification · 95% confidence The document is a market release dated 1 September 2011 from CBio Limited requesting a trading halt pending the release of a material announcement concerning capital raising. It references Listing Rule 17.1 and states the halt is requested until the announcement is made. There is no financial data, report, or detailed announcement included, only a procedural request for trading halt related to capital raising. This fits the category of Capital/Financing Update (CAP) as it concerns capital raising activities and related market procedures.
2011-08-31 English
Preliminary Final Report 20 pages 680.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary Final Report 30 June 2011' and contains detailed financial statements including Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flows, and Notes to Financial Information for the year ended 30 June 2011. It includes comprehensive financial data such as revenue, expenses, net loss, assets, liabilities, equity, and detailed notes on expenses and income tax. The document also mentions that the financial report is in the process of being audited, indicating it is a preliminary final report rather than a fully audited annual report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a financial report rather than a brief announcement or certification. The Appendix 4E is a regulatory filing used in Australia for preliminary final reports, which is a type of annual financial report but not the full annual report (10-K equivalent). Given the detailed financial data and the nature of the report, the best fitting category is Interim / Quarterly Report (IR), as it is a preliminary final report with substantive financial data but not the full audited annual report (10-K). FY 2011
2011-08-30 English
Termination of Convertible Loan Facility 1 page 150
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 25 August 2011 from CBio Limited to the ASX Company Announcements Office. It informs the market that a Convertible Loan Agreement with SpringTree Special Opportunities Fund has been terminated by mutual consent. The text includes background on the company and its clinical trial progress but does not contain any financial statements, detailed financial data, or comprehensive report content. The document is under 5,000 characters and serves as an update on financing arrangements rather than a full financial report or detailed capital structure change announcement. It is not a full Capital/Financing Update (CAP) report but rather a brief regulatory announcement about the termination of a financing agreement. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2011-08-24 English
Repayment of Convertible Note 2 pages 169.6KB
Capital/Financing Update Classification · 95% confidence The document is a formal announcement addressed to the ASX Limited Company Announcements Office, dated 3 August 2011. It informs about the repayment of a convertible note by CBio Limited, specifying the amount repaid and the remaining convertible notes on issue. The content focuses on a specific financing event related to convertible notes, which is a capital structure update. There are no financial statements, comprehensive financial data, or management discussion of results. The document length is 3495 characters, which is relatively short and consistent with an announcement rather than a full report. The nature of the content aligns with updates on company fundraising or capital structure changes, fitting the Capital/Financing Update category. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2011-08-02 English
Headline Clinical Trial Results 4 pages 381.1KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated 31 July 2011 from CBio Limited to the ASX Limited Company Announcements Office. It details headline results from a Phase IIa clinical trial of the drug XToll® for rheumatoid arthritis. The content focuses on clinical trial results, safety profile, and future plans for further trials and commercial discussions. There are no financial statements, regulatory certifications, or detailed financial data. The document is a corporate announcement of clinical trial results rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a specific announcement of clinical trial results, which is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement to the stock exchange about material company developments that do not fit other categories.
2011-07-31 English
Reinstatement to official quotation 1 page 32.1KB
Regulatory Filings Classification · 95% confidence The document is a market release announcing the lifting of suspension of trading for CBio Limited's securities following a clinical trial result announcement. It is a brief regulatory announcement related to stock quotation status, not a financial report or detailed filing. The document length is very short (456 characters), and it does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2011-07-31 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.